ArticleOncogene2026
C-Jun-activated S100A10 promotes malignant progression via in diminishing ubiquitin-dependent degradation of vimentin in gastric cancer.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gastric cancer remains a significant global health challenge. Lymph node metastasis (LNM) has been identified to be relevant to the prognosis of gastric cancer (GC). However, its mechanisms of progression and metastasis are still not fully understood. Recently, S100A10 has been verified to be aberrantly expressed in various cancers. In this study, we found that S100A10 expression was significantly upregulated in metastatic GC tissues. S100A10 remarkably accelerated tumor metastasis and growth. Mechanistically, dual-luciferase assay and chromatin immunoprecipitation revealed that c-Jun could bind to the promoter region of S100A10 and activate its transcription. Meanwhile, S100A10 competitively bound to Vimentin, preventing it from interacting with ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52), which led to a reduction in K48-linked ubiquitination of vimentin and an increase in vimentin protein levels in GC cells. Subcutaneous xenograft and lung metastasis mouse models were established to prove that targeting inhibition of S100A10 could effectively suppressed tumor metastasis and growth in vivo. In conclusion, S100A10, activated by c-Jun, remarkedly promoted metastasis and proliferation in GC via suppressing vimentin-UBA52 interaction.
Indexed as
Identifiers
41786880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.